Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)

Date: April 6, 2020 Issue #:  1595Summary:  The FDA has approved two new drugs for sickle cell disease: crizanlizumab-tmca (Adakveo– Novartis), an IV P-selectin blocker, and voxelotor (Oxbryta– GBT), an oral hemoglobin S (HbS) polymerization inhibitor.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Adakveo crizanlizumab Droxia Endari Hydrea Hydroxyurea L-glutamine Oxbryta sickle cell disease Siklos voxelotor Source Type: research